Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP003413priorityCriticalpatent/ECSP003413A/en
Publication of ECSP003413ApublicationCriticalpatent/ECSP003413A/en
Medicines That Contain Protein Lipid Enzymes And Other Medicines
(AREA)
Abstract
Se describen los métodos para tratar pacientes que no recibieron tratamiento alguno asi como pacientes que experimentaron algún tratamiento que padecen de CML, para lograr al menos, una respuesta citogénica parcial; los métodos incluyen administrar una cantidad terapéuticamente efectiva de interferón-alfa modificado con PEG por ejemplo, interferón alfa 2b modificado con PEG como monoterapia o asociado con una cantidad terapéuticamente efectiva de Ara-C.Methods of treating patients who received no treatment as well as patients who underwent treatment with CML are described to achieve at least a partial cytogenic response; methods include administering a therapeutically effective amount of PEG modified interferon-alpha eg, PEG modified interferon alpha 2b as monotherapy or associated with a therapeutically effective amount of Ara-C.
ECSP0034132000-04-052000-04-05
THERAPY FOR CHRONIC MYELOCITIC LEUKEMIA
ECSP003413A
(en)